



Proteomics International

LABORATORIES LTD

ASX Release

21 June 2018

ASX code: PIQ

Further information following new licence deals for diabetic kidney disease predictive test in USA and Mexico

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has just signed licence agreements for its world-leading PromarkerD predictive test for diabetic kidney disease with USA [ASX: 28 May 2018] and Mexico [ASX: 18 June 2018] partners.

PromarkerD, the first test able to predict the onset of diabetic kidney disease and able to warn of a decline in kidney function up to four years in advance, can offer accurate testing of the more than 43 million people with diabetes in the USA and Mexico.

About the USA licence agreement with PrismHealthDx, Inc. (PHDx) [ASX: 28 May 2018]

- USA PromarkerD launch targets the world's biggest spending country on diabetes care
- Test to be offered to patients through a partnership with precision medicine and diagnostic services laboratory PrismHealthDx, Inc. (PHDx)
- The licence is for the "Laboratory Developed Test" (LDT) mass spectrometry version of PromarkerD, and is exclusive for 1 year in the USA.
- PHDx will launch the PromarkerD test nationally.

About the Mexico licence agreement with Patia Biopharma (Patia) [ASX: 18 June 2018]

- Mexico has one of the highest rates of diabetes in the world, with 13 million adults suffering from the condition
- Test to be offered to patients through a partnership with Patia BioPharma, a company focused on promoting personalised preventive medicine
- The licence is for the "Laboratory Developed Test" (LDT) mass spectrometry version of PromarkerD, and is exclusive for 3 years in Mexico.
- Through Patia's network the test will initially be introduced to private hospitals and private clinics, and then expanded into government hospitals and Carlos Slim Foundation programs.

Under each national licence agreement, the partner will develop and commercialise the PromarkerD test in its specialist certified laboratories. First sales under each agreement are anticipated to be in four to six months, and Proteomics International will receive a royalty on all tests sold. Further details of the licence agreement are commercially sensitive and remain confidential.

Ten percent of people living with diabetes are expected to suffer a rapid decline in kidney function within four years. The PromarkerD test is able to predict this decline in kidney function in 86 per cent of cases. If every one of the 43 million Americans and Mexicans with diabetes took the test it would potentially identify 3.7 million of the 4.3 million people on the path to kidney disease. Those identified would also require systematic retesting to verify effectiveness of treatments. As for any novel test, market penetration cannot be predicted accurately, hence for both new licences it is not possible to quantify the financial impact on Proteomics International in any given timeframe.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

PromarkerD has the potential to spare millions of people from future dialysis costs, and save each healthcare system billions of dollars. Consequently, the Directors of Proteomics International believe that ultimately the financial impact of each licence will be significant.

The issuance of licences in different countries is consistent with Proteomics International's stated business model of generating revenue from its intellectual property.

Discussions are ongoing with other potential partners, and Proteomics International Managing Director Dr Richard Lipscombe will attend the American Diabetes Association 78th Scientific Sessions (June 22-26, 2018, Orlando, Florida) to discuss PromarkerD licence deals.

ENDS

About PromarkerD (www.PromarkerD.com)

PromarkerD is a predictive diagnostic test for diabetic kidney disease. In clinical studies presented in 2017 at the American Diabetes Association Annual Scientific Sessions [ASX: 10 June 2017] and published in the prestigious journal Diabetes Care [ASX: 6 September 2017], PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. PromarkerD has been rated the world's leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its report titled Biomarkers Enabling Diabetes and Obesity Management [ASX: 27 March 2017]. PromarkerD has received patent protection in several major jurisdictions including the USA, China, Europe, and Japan, with others pending.

Further information is available through the PromarkerD web portal.

About PHDx, Inc (www.phdxinc.com)

PrismHealthDx, Inc. (PHDx) is a precision medicine diagnostic laboratory and services company specialising in comprehensive biomarker testing to detect the onset of disease and serious medical conditions at their earliest and most treatable stage. PHDx provides a 'one-stop-shop' opportunity to integrate best-in-class laboratory and clinical medicine into practices, driving better clinical outcomes and helping to make an immediate difference in the lives of their patients. PHDx's management team has extensive experience in developing and commercialising novel assays and they are committed to advancing new diagnostic and disease management capabilities. PHDx works in partnership with academic leaders, industry leaders, and clinical providers.

About Patia Biopharma (www.patiadiabetes.com)

Patia Biopharma is a Mexican company focused on promoting personalised preventive medicine across Mexico, Latin America and worldwide. Patia offers the medical community a vast array of genomic, metabolomic and proteomic tests for risk assessment and early diagnosis, which support early interventions in patients with diabetes.

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Susan Fitzpatrick-Napier
[Public Relations & Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com